GlassScriptPhysician profile
David Edward Kaplan
NPI 1730193475
$26,382.77
in general payments reported to CMS, 2019-2025
13 companies · $2,443 in 2025
The $2,443 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,769 · 2020: $1,000 · 2022: $236 · 2023: $3,708 · 2024: $15K · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,295 · Food and Beverage: $725 · Travel and Lodging: $73.94 · Education: $18.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,265.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,295.00 |
| Food and Beverage | $724.78 |
| Travel and Lodging | $73.94 |
| Education | $18.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $9,660.00 | 2024 | |
| Madrigal Pharmaceuticals | $6,135.06 | 2024-2025 | Rezdiffra |
| Exelixis INC. | $5,426.08 | 2019-2023 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $3,624.21 | 2022-2024 | Imfinzi |
| Genentech USA, INC. | $1,000.00 | 2020 | |
| Eisai INC. | $249.05 | 2019-2024 | |
| Mirum Pharmaceuticals, INC. | $124.05 | 2023-2024 | Livmarli |
| Mallinckrodt Hospital Products INC. | $120.41 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.52 | 2024 | Xifaxan |
| Boston Scientific Corporation | $12.39 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.